Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: Implications of genetic variants on pharmacokinetics and hyperbilirubinemia

Clinical Cancer Research

Volumn 18, Issue 7, 2012, Pages 2099-2107

  Peer, Cody J ^a   Sissung, Tristan M ^a   Kim, AeRang ^a   Jain, Lokesh ^a   Woo, Sukyung ^a   Gardner, Erin R ^a   Kirkland, C Tyler ^a   Troutman, Sarah M ^a   English, Bevin C ^a   Richardson, Emily D ^a   Federspiel, Joel ^a   Venzon, David ^a   Dahut, William ^a   Kohn, Elise ^a   Kummar, Shivaani ^a   Yarchoan, Robert ^a   Giaccone, Giuseppe ^a   Widemann, Brigitte ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A9; RITONAVIR; SORAFENIB;

ADULT; AGED; ALLELE; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CASE REPORT; COLORECTAL CANCER; CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG EXPOSURE; DRUG GLUCURONIDATION; DRUG INHIBITION; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERBILIRUBINEMIA; IC 50; IN VITRO STUDY; KAPOSI SARCOMA; LABORATORY TEST; LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; MALE; MASS SPECTROMETRY; PHARMACOGENETICS; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN METABOLISM; UGT1A1 GENE;

AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BENZENESULFONATES; BILIRUBIN; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; HYPERBILIRUBINEMIA; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS; PHARMACOGENETICS; PILOT PROJECTS; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; PYRIDINES;

EID: 84859402733     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2484     Document Type: Article

References (32)

1. Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 2010;29:95.
2. Aragon-Ching JB, Jain L, Gulley JL, Arlen PM, Wright JJ, Steinberg SM, et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 2009;103:1636-40.
3. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008;26:3709-14.
4. Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008;14:209-14. (Pubitemid 351377997)
5. Jain L, Venitz J, Figg WD. Randomized discontinuation trial of sorafenib (BAY 43-9006). Cancer Biol Ther 2006;5:1270-2. (Pubitemid 44772249)
6. Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006;57:685-92.
7. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009;69:223-40.
8. Nexavar (Sorafenib) Prescribing Information, Bayer Pharmaceuticals. 2009. Available from: http://www.nexavar.com/html/download/Nexavar-PI.pdf
9. Girard H, Villeneuve L, Court MH, Fortier LC, Caron P, Hao Q, et al. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab Dispos 2006;34:1220-8.
10. Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, et al. Population pharmacokinetic analysis of sorafenib in patients with solid tumors. Br J Clin Pharmacol 2011;72:294-305.
11. European Public Assessment Reports (EPAR)-Scientific Discussion. 2009. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--- Scientific-Discussion/human/000690/WC500027707.pdf
12. Parsa V, Heilbrun L, Smith D, Sethi A, Vaishampayan U. Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function. Clin Genitourin Cancer 2009;7:E10-5.
13. Strassburg CP. Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome). Best Pract Res Clin Gastroenterol 2010;24:555-71.
14. Meza-Junco J, Chu QS, Christensen O, Rajagopalan P, Das S, Stefanyschyn R, et al. UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. Cancer Chemother Pharmacol 2009;65:1-4.
15. Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009;27:1800-5.
16. Abou-Alfa GK, Amadori D, Santoro A, Figer A, De Greve J, Lathia C, et al. Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis. Gastrointest Cancer Res 2011;4:40-4.
17. Mross K, Steinbild S, Baas F, Gmehling D, Radtke M, Voliotis D, et al. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 2007;43:55-63. (Pubitemid 46054474)
18. Dasanu CA, Alexandrescu DT, Dutcher J. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. South Med J 2007;100:328-30. (Pubitemid 46673440)
19. Jedlitschky G, Hoffmann U, Kroemer HK. Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin Drug Metab Toxicol 2006;2:351-66. (Pubitemid 46141403)
20. Kelly RJ, Rajan A, Force J, Keen C, Cao L, Yu Y, et al. Evaluation of KRASmutations, angiogenic biomarkers and DCE-MRI in patients with advanced non-small cell lung cancer receiving sorafenib. Clin Cancer Res 2011;17:1190-9.
21. Gutierrez M, Kummar S, Allen D, Turkbey B, Choyke P, Wright JJ, et al. A phase II study of multikinase inhibitor sorafenib in patients with relapsed non-small cell lun cancer (NSCLC) [abstract]. In: Proceedings of the 2008 ASCO Annual Meeting; 2008 May 20; Chicago, IL: ASCO; 2008. Abstract nr 19084.
22. Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009;15:1411-6.
23. Kim ADE, Tepas K, Fox E, Balis FM, Korf B, Widemann BC. Phase I trial of sorafenib in children with neurofibromatosis type I and inoperable plexiform neurofibromas [abstract: Drug06]. Neuro-Oncology 2010;12:ii42.
24. Widemann BC, Fox E, Adamson PC, Baruchel S, Kim A, Ingle AM, et al. Phase I study of sorafenib in children with refractory solid tumors: a Children's Oncology Group Phase I Consortium Trial [abstract]. In: Proceedings of the 2009 ASCO Annual Meeting; 2009; Chicago, IL: ASCO; 2009. Abstract nr 10012.
25. Senafi SB, Clarke DJ, Burchell B. Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem J 1994;303:233-40. (Pubitemid 24302924)
26. Seppen J, Bosma PJ, Goldhoorn BG, Bakker CT, Chowdhury JR, Chowdhury NR, et al. Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. J Clin Invest 1994;94:2385-91. (Pubitemid 24379612)
27. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005;33:1729-39. (Pubitemid 41539973)
28. Udomuksorn W, Elliot DJ, Lewis BC, Mackenzie PI, Yoovathaworn K, Miners JO. Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics 2007;17:1017-29. (Pubitemid 351339486)
29. Jinno H, Tanaka-Kagawa T, Hanioka N, Saeki M, Ishida S, Nishimura T, et al. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos 2003;31:108-13. (Pubitemid 36735264)
30. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:426-37. (Pubitemid 46698720)
31. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009;15:6062-9.
32. Rubin GM, Tozer TN. Hepatic binding and Michaelis-Menten metabolism of drugs. J Pharm Sci 1986;75:660-3. (Pubitemid 16038894)